Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: Systematic review and meta-analysis of randomised controlled trials

The BMJ

Volumn 366, Issue , 2019, Pages

  Feng, Qi ^a   Zhou, Aoshuang ^a   Zou, Huachun ^b,c   Ingle, Suzanne ^d   May, Margaret T ^d   Cai, Weiping ^e   Cheng, Chien Yu ^f,g   Yang, Zuyao ^a   Tang, Jinling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e Guangzhou Eighth People's Hospital   (China)

^f TAO YUAN GENERAL HOSPITAL   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; INDIVAVIR; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VIRUS LOAD; COMBINATION DRUG THERAPY;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85068827266     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.l4179     Document Type: Article

References (48)

1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980- 2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151-210. doi:10.1016/S0140- 6736(17)32152-9
2. World Health Organization. Summary of the global HIV epidemic (2017). https://www.who.int/hiv/data/en/Accessed 05 Dec 2018.
3. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: Combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis 2013;208:224-34. doi:10.1093/infdis/jit150
4. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in highincome countries: A collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9. doi:10.1016/S0140-6736(08)61113-7
5. Jin Y, Liu Z, Wang X, et al. A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy. Int J STD AIDS 2014;25:771-7. doi:10.1177/0956462414525769
6. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A populationbased study. Lancet 2010;376:532-9. doi:10.1016/S0140- 6736(10)60936-1
7. Naftalin CM, Wong NS, Chan DP, Wong KH, Reidpath DD, Lee SS. Three different patterns of CD4 recovery in a cohort of Chinese HIV patients following antiretroviral therapy - A five-year observational study. Int J STD AIDS 2015;26:803-9. doi:10.1177/0956462414553826
8. Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: A meta-analysis. HIV Med 2017;18:256-66. doi:10.1111/hiv.12421
9. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: Comparisons with general population. Curr Opin HIV AIDS 2016;11:492-500. doi:10.1097/COH.0000000000000298
10. Pau AK, George JM. Antiretroviral therapy: Current drugs. Infect Dis Clin North Am 2014;28:371-402. doi:10.1016/j.idc.2014.06.001
11. Jordan R, Gold L, Cummins C, Hyde C. Systematic review and metaanalysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002;324:757. doi:10.1136/bmj.324.7340.757
12. Fischl MA, Ribaudo HJ, Collier AC, et al, Adult AIDS Clinical Trials Group 388 Study Team. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003;188:625-34. doi:10.1086/377311
13. Serrano-Villar S, Sainz T, Ma ZM, et al. Effects of combined CCR5/integrase inhibitors-based regimen on mucosal immunity in HIV-Infected patients naïve to antiretroviral therapy: A pilot randomized trial [correction in: PLoS Pathog 2016;12:e1005540 and 2017;13:e1006368]. PLoS Pathog 2016;12:e1005381. doi:10.1371/journal.ppat.1005381
14. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2nd ed. WHO, 2016. https://www.who.int/hiv/pub/arv/arv-2016/en/Accessed 05 Dec 2018.
15. Günthard HF, Aberg JA, Eron JJ, et al, International Antiviral Society- USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312:410-25. doi:10.1001/jama.2014.8722
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services, 2017. https://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed 05 Dec 2018.
17. European AIDS Clinical Society. Guidelines. Version 9.0. Oct 2017. www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines. html Accessed 05 Dec 2018.
18. Lund H, Brunnhuber K, Juhl C, et al. Towards evidence based research. BMJ 2016;355:i5440. doi:10.1136/bmj.i5440
19. Gulick RM, Ribaudo HJ, Shikuma CM, et al, AIDS Clinical Trials Group (ACTG) A5095 Study Team. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA 2006;296:769-81. doi:10.1001/jama.296.7.769
20. Orkin C, Stebbing J, Nelson M, et al. A randomized study comparing a three- And four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 2005;55:246-51. doi:10.1093/jac/dkh515
21. Higgins J, Green S. Cochrane handbook for systematic review of interventions. [Version 5.1.0] Cochrane Collaboration, 2011.
22. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009;62:e1-34. doi:10.1016/j.jclinepi.2009.06.006
23. Kirk O, Katzenstein TL, Gerstoft J, et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial. AIDS 1999;13:F9-16. doi:10.1097/00002030-199901140-00002
24. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9. doi:10.1093/jac/dkh029
25. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: A systematic review and meta-analysis. Clin Infect Dis 2009;49:1915-27. doi:10.1086/648079
26. Ewald H, Santini-Oliveira M, Bühler JE, et al. Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: Systematic review and meta-analysis. HIV Clin Trials 2017;18:17-27. doi:10.1080/15284336.2016.1261073
27. Hemkens LG, Ewald H, Santini-Oliveira M, et al. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: Systematic review and meta-analysis. HIV Clin Trials 2015;16:178-89. doi:10.1179/1945577115Y.0000000004
28. Higgins JP, Altman DG, Gøtzsche PC, et al, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928
29. Higgins J, Green S. 7.7.3.8 Combining groups. In: Higgins J, Green S, eds. Cochrane handbook for systematic review of interventions. [Version 5.1.0] Cochrane Collabration, 2011.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. doi:10.1136/bmj.327.7414.557
31. Higgins J, Green S. 9.5 heterogeneity. In: Higgins J, Green S, eds. Cochrane handbook for systematic review of interventions. [Version 5.1.0] Cochrane Collabration, 2011.
32. Higgins J, Green S. 10.4.3.1 Recommendations on testing for funnel plot asymmetry. In: Higgins J, Green S, eds. Cochrane handbook for systematic review of interventions. [Version 5.1.0] Cochrane Collabration, 2011.
33. Yeni P, Cooper DA, Aboulker JP, et al, INITIO Trial International Coordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: Open-label randomised trial. Lancet 2006;368:287-98. doi:10.1016/S0140-6736(06)69074-0
34. Joly V, Fagard C, Grondin C, et al, S 130 Apollo Trial Group. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: Results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother 2013;57:758-65. doi:10.1128/AAC.01662-12
35. Kirk O, Lundgren JD, Pedersen C, et al. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Antivir Ther 2003;8:595-602.
36. Moyle G, Higgs C, Teague A, et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther 2006;11:73-8.
37. Portilla J, Boix V, Garcia-Henarejos JA, et al. Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy. Int J STD AIDS 2005;16:807-10. doi:10.1258/095646205774988082
38. Puertas MC, Massanella M, Llibre JM, et al, MaraviBoost Collaborative Group. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014;28:325-34. doi:10.1097/QAD.0000000000000066
39. Sierra-Madero JG, Ellenberg S, Rassool MS, et al, CADIRIS study team. A randomized, double-blind, placebo-controlled clinical trial of a chemokine receptor 5 (CCR5) antagonist to decrease the occurrence of immune reconstitution inflammatory syndrome in HIV-infection: The CADIRIS Study. Lancet HIV 2014;1:e60-7. doi:10.1016/S2352- 3018(14)70027-X
40. van Leth F, Phanuphak P, Ruxrungtham K, et al, 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63. doi:10.1016/S0140-6736(04)15997-7
41. Mora-Peris B, Bouliotis G, Ranjababu K, et al. Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. AIDS 2018;32:1007-15. doi:10.1097/QAD.0000000000001786
42. Del Prete GQ, Smedley J, Macallister R, et al. Short communication: Comparative evaluation of coformulated injectable combination antiretroviral therapy regimens in simian immunodeficiency virus-infected rhesus macaques. AIDS Res Hum Retroviruses 2016;32:163-8. doi:10.1089/aid.2015.0130
43. Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: A systematic review and network meta-analysis. Lancet HIV 2016;3:e510-20. doi:10.1016/S2352-3018(16)30091-1
44. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37:1112-8. doi:10.1086/378301
45. Nachega JB, Marconi VC, van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: Evolving concepts. Infect Disord Drug Targets 2011;11:167-74. doi:10.2174/187152611795589663
46. ClinicalTrial.gov. Antiretroviral therapy for acute and chronic HIV infection (NCT00796263) 2018 https://www.clinicaltrials.gov/ct2/history/NCT00796263?V-12=View#StudyPageTop.
47. Markowitz M, Evering TH, Garmon D, et al. A randomized openlabel study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 2014;66:140-7. doi:10.1097/QAI.0000000000000111
48. Ananworanich J, Chomont N, Fletcher JL, et al. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. J Virus Erad 2015;1:116-22.